Kairos signs IIR agreement with Bayer

Kairos Pharma entered into an investigator-initiated research agreement with Bayer to conduct a clinical study, eliminating immediate revenue impact from the deal. The non-binding nature of the agreement precludes triggering of material financial disclosures under certain SEC rules.